Gilead Stock News

Gilead Sciences (GILD) reachead $79.07 at the closing of the latest trading day, reflecting a -0.57% change compared to its last close.

Gilead Sciences said on Monday it has raised its stake in Arcus Biosciences to 33% and expanded its presence in the drug developer's board to three, deepening their collaboration in developing cancer

Embracing The Mania And Yield At A Reasonable Price

Gilead Sciences (GILD) concluded the recent trading session at $79.48, signifying a +1.34% move from its prior day's close.

Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.

The FDA directs companies like NVS, BMY, GILD and others to add "boxed warning" to the labels of their CAR T-cell immunotherapies after it identified adverse events.

Trodelvy did not perform well in an important clinical trial. Management is vowing to keep seeking other patient populations to treat with the drug.

George Ball, chairman at Sanders Morris Harris, joins 'Power Lunch' to discuss Ball's investment take on three stocks: Affirm Holdings, Gilead Sciences, and 3M.

Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) shares fell by their most since 2015 as the late-stage trial of its antibody-drug conjugate Trodelvy failed to show a significant improvement in the overall

Gilead will discuss the results with regulators and identify whether certain lung cancer patients may still benefit from the drug, known as Trodelvy.

Gilead Sciences Inc (NASDAQ: GILD) says its drug conjugate Trodelvy disappointed in a late-stage cancer trial. Shares of the biotech firm opened about 10% down today.

Shares of Gilead Sciences Inc. GILD, +1.03% tumbled 10.9% beating in premarket trading Monday, to pullback from an 11-month high, after the biotechnology company disappointing trial results of its lun

Gilead Sciences on Monday said a late-stage trial of its antibody-drug conjugate Trodelvy failed to show that it significantly improved survival for previously treated patients with advanced non-small

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $86.48, denoting a +0.57% change from the preceding trading day.

Jenny Harrington, Gilman Hill Asset Management CEO, Jim Lebenthal, chief equity strategist at Cerity Partners, Joe Terranova, senior managing director at Virtus Investment Partners, and Rob Sechan, ma